🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07368335
Active, not recruiting Not applicable

Efficacy and Safety of a Novel ERCP Robot in the Treatment of Common Bile Duct Stone

NCT07368335 · tracked via the Priya Life Science China tracker
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase
Not applicable
Started
2025-12-24
Last updated
2026-01-26

Condition(s) studied

ERCPRobot SurgeryCommon Bile Duct Stone

Investigational drug(s) / intervention(s)

Robotic-assisted ERCPConventional ERCP

Robotic-assisted ERCP: This group will receive endoscopic common bile duct lithotomy using the Electronic Endoscopic Surgery System produced by Shanghai Aohua Endoscopy Co., Ltd.

Conventional ERCP: This group will undergo conventional endoscopic common bile duct lithotomy with a regular electronic duodenoscope.

Study summary

Conventional endoscopic retrograde cholangiopancreatography (ERCP) is performed under fluoroscopic guidance, exposing endoscopists to ionizing radiation and posing risks of work-related musculoskeletal injury. Robotic-assisted ERCP may mitigate these occupational hazards and potentially enhance procedural precision and stability. However, robust clinical evidence regarding its performance and safety remains limited. This prospective, multicenter, randomized controlled non-inferiority trial is designed to evaluate the efficacy and safety of an ERCP robotic system (Electronic Endoscopic Surgery System) developed by Shanghai Aohua Photoelectricity Endoscope Co., Ltd. for common bile duct stone removal. A total of at least 200 subjects will be recruited and randomized 1:1 to either the experimental group or the control group. The experimental group will undergo robotic-assisted ERCP lithotomy using the aforementioned system, while the control group will receive conventional ERCP lithotomy using a standard duodenoscope.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Aged 18 to 80 years, inclusive. 2. Diagnosed with common bile duct stones based on symptoms, signs, laboratory tests, and imaging examinations, and deemed suitable by the investigator for endoscopic common bile duct stone removal (lithotomy). 3. Willing to comply with all study procedures; able to understand the study purpose, and voluntarily provide written informed consent. Exclusion Criteria: 1. Severe cardiac, pulmonary, renal, or hepatic insufficiency, or mental disorders. 2. Active viral hepatitis. 3. Upper gastrointestinal stenosis, obstruction, or any condition preventing endoscopic access to the descending duodenum. 4. Known intolerance to anesthetics or hypersensitivity to contrast agents. 5. Non-lithogenic obstructive acute pancreatitis or acute exacerbation of chronic pancreatitis. 6. Pregnant or lactating women. 7. Active peptic ulcer or upper gastrointestinal hemorrhage within one month prior to informed consent. 8. Known severe bleeding tendency (coagulopathy). 9. History of upper gastrointestinal reconstruction surgery resulting in altered anatomy. 10. Previous endoscopic sphincterotomy of the duodenal papilla. 11. Inability to cooperate with ERCP procedures. 12. Participation in a drug clinical trial within the past 3 months, or in another medical device clinical trial (excluding non-interventional studies) within the past month. 13. Any other condition that, in the opinion of the investigator, may render the participant unsuitable for the trial (including but not limited to duodenal mucosal edema, papillary malformation, papillary surface ulcer, papillary fistula, or difficult-to-treat stones).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu

More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07368335 on ClinicalTrials.gov ↗ ← All trials in China